Targeting hMGL-GalNAc interactions to reverse immune suppression in cancer

Project description

Inhibiting immune suppression in cancer

Tumours are known to evade immune responses, thereby limiting the efficacy of immunotherapy and vaccination efforts. Although cancer cells express aberrant glycosylation patterns, their immunosuppressive role has been largely overlooked. The EU-funded MGLycan project will focus on the macrophage galactose-type lectin (MGL), the key receptor on immune cells that recognises aberrant sugars on cancer cells. MGL is overexpressed in macrophages and dendritic cells during immune suppression. The main objective of the project is to design inhibitors that block the MGL interaction with cancer cells, blocking downstream signalling that culminates in immune suppression.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines
• natural sciences › biological sciences › biochemistry › biomolecules › carbohydrates
• medical and health sciences › clinical medicine › oncology
• medical and health sciences › basic medicine › immunology › immunotherapy

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2018 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2018

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE

Net EU contribution

€ 172 932,48

Address

Paseo Miramon 182, Parque Tecnologico De San Sebastian Edificio Empresarial C
20009 San Sebastian
Spain

Region

Noreste › País Vasco › Gipuzkoa

Activity type

Research Organisations

Links

Other funding

€ 0,00